Kornimate/medical-research-clean huggingface dataset:
investigation of the effect of information on the empowerment of cancer patients using question prompt list: a mixed method study

Conditions: Neoplasms (Cancer / Tumors); Patient Participation; Patient-Centered Care; Health Communication; Patient Empowerment; Anxiety

Summary: brief summary the goal of this study is to understand how patient empowerment and a question prompt list (qpl) can help cancer patients. the main questions this study aims to answer are: what are the views of nurses, physicians, and cancer patients on patient empowerment? does using a question prompt list (qpl) improve patient empowerment and reduce anxiety? researchers will collect qualitative and quantitative data by measuring patient empowerment and anxiety levels. who can participate? cancer patients receiving treatment at private anadolu medical center hospital nurses and physicians working with cancer patients what will participants do? answer survey questions about their experiences with empowerment, anxiety, and communication participate in interviews to share their thoughts on patient empowerment use a question prompt list (qpl) during medical consultations why is this study important? many cancer patients struggle with anxiety and lack of information about their care. a question prompt list (qpl) may help patients ask better questions, feel more in control of their treatment, and reduce anxiety. this study will contribute to oncology research and help develop a culture-specific qpl for use in cancer care. this study will take place at private anadolu medical center hospital from january 2023 to november 2024.


Eligibility criteria:
inclusion criteria: * patients must be over 18 years old. * must understand and speak turkish. * must not have any condition preventing participation (e.g., advanced dementia, cognitive impairment, speech or hearing disorders). * for healthcare professionals in the qualitative phase: must have at least one year of experience in oncology. exclusion criteria: * patients without regular outpatient follow-up visits. * patients with severe cognitive or physiological deterioration affecting participation. * patients who do not comply with the study process and requirements. * patients who voluntarily request to withdraw from the study.
solifenacin succinate (vesicare) for the treatment of urinary incontinence in parkinson's disease

Conditions: Urinary Incontinence; Parkinson's Disease

Summary: the primary purpose of this study is to measure the efficacy of solifenacin succinate (vesicare) on treating urinary incontinence in parkinson's disease patients. the secondary objective of this study is to examine the effect of solifenacin succinate (vesicare) on symptoms of pd and the patient's quality of life.


Eligibility criteria:
inclusion criteria: 1. outpatients with idiopathic pd according to the uk parkinson's disease society brain bank clinical diagnosis criteria. 2. age 30 years to 80 years. 3. stable dose of antiparkinsonian medication 4 weeks prior to study entry. 4. patients must score 18 or higher on the updrs scale and 1.0 to 2.5 on the modified hoehn and yahr scale. 5. women of child-bearing potential must use a reliable method of contraception. 6. must be experiencing symptoms of urinary incontinence (voiding 8 or more times/day or episodes of incontinence 5 or more times per week). 7. patients must have evidence of normal psa and urodynamic tests within the last 12 months. 8. clearance from the patient's urologist or internist who has examined the patient within the last 12-months. exclusion criteria: 1. any illness that in the investigator's opinion preclude participation in this study. 2. pregnancy or lactation. 3. concurrent participation in another clinical study. 4. dementia or other psychiatric illness that prevents the patient from giving informed consent (mini mental status exam score less than 24). 5. legal incapacity or limited legal capacity. 6. presence of severe renal disease (bun 50% greater than normal). 7. presence of major hepatic impairment. 8. currently taking ketaconazole (anti-fungal) or any cyp3a4 inhibitor. 9. any history of bladder outflow obstruction or gastrointestinal obstructive disorders. 10. history of controlled narrow angle glaucoma.

Keywords: urinary incontinence parkinson's disease vesicare solifenacin succinate
use of ketamine associate with an opioid for sedation in icu

Conditions: Sedation for Mechanical Ventilation

Summary: the aim of the study is to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. sedation will be drive by nurses according to an algorithm. the investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.

all consecutive mechanically ventilated patients admitted in the intensive care unit (icu)will be randomized to receive an infusion of 0.15 mg/kg/h of kétamine or placebo. nurses and physicians will be blinded of the allocation arm. the infusion of ketamine will be stopped as soon as remifentanil will be discontinued by the physician.

Eligibility criteria:
inclusion criteria: * all patients under mechanical ventilation exclusion criteria: * pregnant * psychotic * chronic use of opiates * age \< 18 years

Keywords: sedation icu ketamine confusion hyperalgesia
robotics for rehabilitation of hand and fingers after stroke

Conditions: Stroke

Summary: the major issue for a person who has suffered a stroke is the severe impairment affecting the hand and the high risk to have a poor recovery associated. innovative approaches are needed in the next future, translating recent advances from neuro-engineering, into feasible devices for rehabilitation care. the fp7-eu project myosens aims to translate known motor control logic from semg prosthetic control, to rehabilitation robotics. the target is to promote the closing of sensory-motor loop on the basis of intention to move, as detected from residual semg (i.e. extensor digitorum communis, flexor digitorum profundus).

the objectives of this pilot study are: * to assess whether a clinical and kinematic effect might be induced providing a closed-loop control by semg signal for robot (i.e. amadeo ®) assisted therapy of hand function * to determine safety and feasibility of including robotic therapy into daily rehabilitation programs after stroke. a total of 20 patients has been recruited, all of them received on daily basis 1 hour of robot therapy in adjunction to 1 hour of standard therapy. overall the hour of robotic therapy include both subject preparation (15 minutes to place surface electrodes on the forearm and set the right position of sitting and upper limb) and delivery of exercises. the treatment protocol includes passive and active training of flexion and extension movements of the fingers. the passive part lasts 5 minutes, while the active one provides 25 total minutes divided into 5 exercises. the robot therapy lasts 15 consecutive sessions, 5 times a week, for 3 weeks.

Eligibility criteria:
inclusion criteria: * patients suffering from first stroke, ischemic and/or hemorrhagic * score between 1 and 3 at the upper-limb sub-item of the italian version of the national institute of health stroke scale, it-nihss (pezzella et al. 2009) * score lower than 100 out of a total of 126 at the functional independence measure (fim) scale. * less than 45 cubes carried in one minute whit the affected hand at the box and bocks test. exclusion criteria: * non-stabilized fractures * diagnosis of depression * traumatic brain injury * untreated or drug resistant seizures. * severe ideomotor apraxia * severe neglect * patients participating in other rehabilitation treatments for the upper-limb (e.g. virtual reality treatment, motor imagery).

Keywords: hand rehabilitation semg
ahmed glaucoma valve alone, with amniotic membrane or with mitomycin c (mmc) for treatment of refractory glaucoma

Conditions: Refractory Glaucoma

Summary: this randomized, controlled trial (rct) compares the efficacy and safety of ahmed glaucoma valve (agv) implantation alone, with 3 minutes mmc application or with a single layer coverage of amniotic membrane. outcomes include intraocular eye pressure (iop), postoperative glaucoma medication and complications. agv implantation site will be superior or inferior based on indication and these groups will be randomized separately.


Eligibility criteria:
inclusion criteria: * patients with refractory glaucoma exclusion criteria: * children under 7 years old * adults above 75 years old * uncooperative patients * patients underwent the operation for second time * patients with major operation with agv
respiratory and cardiovascular alterations in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease Moderate; Chronic Obstructive Pulmonary Disease Severe; Cardiovascular Diseases; Quality of Life

Summary: chronic obstructive pulmonary disease (copd) is a major cause of disability and death worldwide. people with copd often have cardiovascular diseases (cvds) that are associated with increased risk for hospitalization and prolonged stay as well as all-cause and cvd-related mortality. nevertheless, cvds in patients with copd are tend to be underestimated in clinical practice. mechanisms that define the relation between copd and cardiovascular morbidity include lung hyperinflation, hypoxia, pulmonary hypertension, systemic inflammation and oxidative stress, exacerbation, shared risk factors and copd phenotypes. recently, some authors have announced that copd treatment with dual bronchodilation may not only improve pulmonary function and quality of life, but also have a positive effect on cardiac function in cardiac magnetic resonance imaging (mri) or two-dimensional cardiac ultrasound for the assessments. the aim of this study is to specify the state of respiratory and cardiovascular systems as well as exercise capacity and quality of life in patients with newly diagnosed moderate-to-severe copd and to evaluate their changes after short-term treatment with dual bronchodilation. we hypothesize that patients with newly diagnosed copd and no previous records of cardiac diseases and no apparent signs of heart failure have significantly impaired cardiac autonomic integrity that precedes to increased risk of cardiovascular events. it is believed that cardiac autonomic integrity might significantly improve with dual bronchodilation therapy.


Eligibility criteria:
inclusion criteria: * aged 40 years and older * smoking index of 10 pack-years and more * newly diagnosed chronic obstructive pulmonary disease (copd) with forced expiratory volume in 1 second (fev1) 30-79 percent of predicted and forced expiratory volume in 1 second to forced vital capacity ratio (fev1/fvc) less than 70 percent of predicted. exclusion criteria: * active lung infection * present or previously treated lung cancer * alpha-1 antitrypsin deficiency * diagnosed interstitial lung disease * previously diagnosed asthma * diagnosed chronic hypercapnic respiratory failure * treatment with systemic glucocorticoids * unstable ischaemic heart disease * pregnancy * present cardiac arrhythmias * uncontrolled arterial hypertension * dementia and other mental states that determine patient's inability to consent * other medical conditions that in the opinion of the investigator disqualify the subject for inclusion

Keywords: copd cardiac autonomic integrity cardiac function dual bronchodilation biomarkers quality of life
three-dimensional cleft lip and palate morphology prior to one-stage cleft repair

Conditions: Cleft Lip and Palate; Cleft Palate; Craniofacial Deformity

Summary: this is a prospective observational cohort study of consecutive patients with cleft lip and palate deformity undergoing cleft repair at the institute of mother and child in warsaw. cleft morphology will be captured with photo and intraoral camera before routine surgery at around 8 months. furthermore, wound healing at 3 months postoperative will be assessed.


Eligibility criteria:
inclusion criteria: * patients with orofacial cleft, who undergo routine cleft repair exclusion criteria: * missing datasets * no signed consent for research

Keywords: cleft lip and palate presurgical orthopedics cleft morphology palatal plate
adaptive non-invasive ventilation to abolish tidal flow limitation

Conditions: Pulmonary Disease, Chronic Obstructive; Hypercapnia; Ventilator Lung

Summary: this study aimed to evaluate the effects of a novel automatic non-invasive ventilation (niv) mode that continuously adjusts expiratory positive airway pressure (epap) to the lowest value that abolishes tidal expiratory flow limitation. the investigators conducted a prospective, randomized, cross-over study on stable chronic obstructive pulmonary disease (copd) patients. patients were studied in the hospital during two non-consecutive nights while using either fixed or adaptive epap. the primary outcome was the transcutaneous partial pressure of carbon dioxide. secondary outcomes were: oxygen saturation, breathing pattern, oscillatory mechanics, patient-ventilation asynchronies, sleep quality and sleep-related respiratory events.

study design: prospective, randomized, cross-over study. study population: moderate to severe copd patients, long-term users of nocturnal non-invasive ventilation for chronic hypercapnic respiratory failure. inclusion criteria: age\<85 years; presence of tidal expiratory flow limitation in the supine position at an expiratory positive airway pressure of 4 cmh2o. exclusion criteria: copd exacerbation within the past two months; acute illness; clinical instability. study protocol: patients were studied in the hospital over 2 non-consecutive nights while using either fixed or automatic epap. ventilation strategy: pressure-controlled niv was delivered using a non-commercial version of bipap synchrony ventilator (philips-respironics) via an unvented facial mask (amara, philips-respironics). the ventilator evaluated the presence of tidal expiratory flow limitation by the forced oscillation technique. in the automatic-epap mode, the ventilator continuously adjusted epap to the minimum level able to abolish tidal expiratory flow limitation, with a minimum epap of 4 cmh2o and keeping the pressure support constant. measurements: during each study night, the investigators recorded transcutaneous partial pressure of carbon dioxide and oxygen saturation (tosca, radiometer) continuously. airway opening pressure, flow and volume tracings were exported from the ventilator. full laboratory polysomnography (alice5, philips-respironics) was performed according to the american academy of sleep medicine recommendations. data analysis: the investigators compared parameters from the two nights using wilcoxon signed-rank test. p-values \<0.05 were considered statistically significant.

Eligibility criteria:
inclusion criteria: * moderate to severe copd (gold 2017); * long-term users of nocturnal non-invasive ventilation for chronic hypercapnic respiratory failure; * presence of tidal expiratory flow limitation in the supine position at an expiratory positive airway pressure of 4 cmh2o. exclusion criteria: * copd exacerbation within the past two months; * acute illness; * clinical instability.
a study of bbi503 in asymptomatic recurrent ovarian cancer patients with ca-125 elevation

Conditions: Cancer; Ovarian Cancer

Summary: this was an open-label, single-arm, phase ii study in which amcasertib (bbi503) was administered to adult, asymptomatic patients with recurrent ovarian cancer who had elevated ca-125.


Eligibility criteria:
key inclusion criteria: 1. histological or cytological confirmation of epithelial ovarian, primary peritoneal, or fallopian cancer from any previous time point. 2. recurrent or relapsed after completion of initial therapy of epithelial ovarian, primary peritoneal, or fallopian cancer from any previous time point (includes completion of surgery with or without postoperative chemotherapy, including maintenance chemotherapy) 3. elevation of ca-125 according to the following definitions: * patients with an elevated ca-125 before chemotherapy and normalization of ca-125 with/after chemotherapy must show evidence of ca-125 greater than or equal to 2 times the upper limit of normal (uln) on 2 occasions at least 1 week apart * patients with an elevated ca-125 before cancer chemotherapy, which never normalizes, must show evidence of ca-125 greater than or equal to 2 times the nadir value on 2 occasions at least 1 week apart * patients with ca-125 in the normal range before cancer chemotherapy must show evidence of ca-125 greater than or equal to 2 times the uln on 2 occasions at least 1 week apart * for patients who have received subsequent treatment for recurrent cancer, "chemotherapy" in the above criteria refers to the most recent round of chemotherapy. 4. patients with a history of ovarian cancer who are asymptomatic and who do not have documented previous ca-125 levels may enroll if the ca-125 is greater than three times the uln on two occasions, at least one week apart 5. eastern cooperative oncology group (ecog) performance status (ps) of 0 key exclusion criteria: 1. symptoms (other than ≤ grade 1 fatigue, anxiety, depression, or other psychological symptoms) that, in the opinion of the treating oncologist, are a direct result of cancer recurrence. (examples of symptoms that would preclude enrollment include unintentional weight loss, ≥ grade 2 fatigue, and new abdominal pain unrelated to operative procedures for the ovarian malignancy.) 2. receiving any other investigational agent that would be considered a treatment for the primary neoplasm. anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents ≤14 days of first dose of study drug 3. major surgery ≤28 days before start of treatment 4. history of another primary malignancy with an associated disease-free interval of less than 5 years, except for curatively treated basal cell or squamous cell carcinoma of the skin or in situ cancer of the cervix.

Keywords: neoplasms
research study for children with a mother or sister with polycystic ovary syndrome

Conditions: Precursors to PCOS

Summary: in this study, we want to find out more about polycystic ovary syndrome(pcos). this is a common problem in about 7% of teenage girls. problems may include irregular periods, extra hair on the face, chest and back areas. it seems that pcos is related to a high level of male hormones and to another problem called metabolic syndrome(mbs). people with mbs may have high blood pressure, low good cholesterol, high blood fats and extra fat around the waist. girls with mbs are at high risk for getting diabetes and heart disease.

once enrolled in the study, you will have a physical exam done. this includes getting a medical history, height, weight, blood pressure and heart rate. we will also listen to your heart and lungs. we will also look at your skin and determine what stage of puberty you are in by looking at your breast growth and body hair. you will also have two (maybe three) blood tests. the first one is an oral glucose tolerance test (ogtt). during this test, we will have you drink an orange sugary drink and then we will draw your blood. the second test is a frequently sampled intravenous glucose tolerance test (fsigt). during this test, we will give you insulin through one iv catheter and then we will draw blood from another iv catheter. the third test that you might have done is an acth test. during this test, we will draw your blood and then you will be given a dose of cortrosyn (a hormone that your body already makes) and then we will draw your blood again. you will also have two scans of your body done during your visit. there will be a dual energy x-ray scan (dexa) and a magnetic resonance imaging scan (mri). you will be placed in the machines and then the scanner will move over your body.

Eligibility criteria:
inclusion criteria: * relatives with polycystic ovary syndrome * no relatives with polycystic ovary syndrome * overweight * white non-hispanic girls exclusion criteria: * chronic illness * smokers * already having periods

Keywords: polycystic ovary syndrome metabolic syndrome pcos children girls daughters sisters irregular periods
real-world study for the safety of albumin-bound paclitaxel in malignant tumors

Conditions: Cancer

Summary: this is a multi-center, prospective, observational study，to evaluate the safety and influencing factors of albumin-bound paclitaxel in the real-world chinese population，and evaluate of the efficacy of albumin-bound paclitaxel in patients with malignant tumors and its impact on quality of life.


Eligibility criteria:
inclusion criteria: * in patients with malignant tumor who have been treated with albumin-bound paclitaxel for the treatment. exclusion criteria: * no
radiation therapy in treating patients with prostate cancer

Conditions: Prostate Cancer

Summary: rationale: radiation therapy uses high-energy x-rays to damage tumor cells. it is not yet known whether standard radiation therapy is more effective than high-dose radiation therapy in treating patients with prostate cancer. purpose: randomized phase iii trial to compare the effectiveness of standard radiation therapy with that of high-dose radiation therapy in treating patients with stage ii or stage iii prostate cancer.

objectives: * compare local tumor control in patients with stage ii or iii prostate cancer treated with neoadjuvant androgen deprivation therapy with standard vs high-dose conformal radiotherapy. * compare the incidence of biochemical failure (prostate-specific antigen (psa) greater than 2 ng/ml at 6 or more months after initiation of radiotherapy and psa rising from nadir level by at least 50%), development of metastases, and survival in patients treated with these regimens. * compare the acute and late radiation-induced side effects of these regimens in this patient population. * compare aspects of quality of life, health economics, models of normal tissue, and tumor control in patients treated with these regimens. outline: this is a randomized, multicenter study. patients are stratified according to prostate-specific antigen, t stage, and gleason score. patients are randomized to one of two treatment arms. all patients receive neoadjuvant androgen deprivation with luteinizing hormone-releasing hormone agonists every 4 weeks beginning 3-6 months before initiation of radiotherapy and continuing until completion of radiotherapy. * arm i: patients undergo standard conformal radiotherapy for 6.5 weeks. * arm ii: patients undergo high-dose conformal radiotherapy for 7.5 weeks. quality of life is assessed at baseline, every 6 months for 2 years, and then annually thereafter. patients are followed every 6 months for 2 years and then annually thereafter. projected accrual: a total of 800 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed prostate cancer * t1b-t3a, n0, m0 (stage ii or iii) * prostate-specific antigen at least 50 ng/ml patient characteristics: age: * not specified performance status: * who 0-1 life expectancy: * not specified hematopoietic: * wbc greater than 4,000/mm\^3 * platelet count greater than 100,000/mm\^3 * hemoglobin greater than 11 g/dl hepatic: * not specified renal: * not specified other: * no significant past medical history that would preclude radical radiotherapy * no condition that would preclude standard radiotherapy * no hip prosthesis prior concurrent therapy: biologic therapy: * not specified chemotherapy: * not specified endocrine therapy: * no prior androgen deprivation therapy radiotherapy: * no prior pelvic radiotherapy surgery: * no prior radical prostatectomy

Keywords: stage iib prostate cancer stage iia prostate cancer stage iii prostate cancer